New approach to CAR T-cell therapy for B-cell cancers triples the targeted antigens on cancer cells
A new approach to CAR T-cell therapy for B-cell cancers triples the targeted antigens on cancer cells (for instance, CD19 antigen). It promises to reduce significantly the potential for antigen escape currently found in CAR-T therapies. Scientists worked together at University Hospitals Seidman Cancer Center and Case Western Reserve University to develop the treatment.
The new B-cell activating factor (BAFF) CAR T product binds specifically to each of three receptors (BAFF-R, BCMA, and TACI) instead of one. At least two of these three receptors are found in almost all B-cell cancers, with some cancers expressing all three. This study published in Nature Communications reported on experiments showing that the BAFF CAR T can kill many B-cell cancers.
ارسال به دوستان